<!doctype html><html lang="zh-hans"><head><meta charset="utf-8"><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"><title>癌症疫苗过山车（2009）The cancer vaccine roller coaster (2009)</title><link rel="stylesheet" href="https://stackpath.bootstrapcdn.com/bootstrap/4.3.1/css/bootstrap.min.css" integrity="sha384-ggOyR0iXCbMQv3Xipma34MD+dH/1fQ784/j6cY/iJTQUOhcWr7x9JvoRxT2MZw1T" crossorigin="anonymous"><link rel="stylesheet" href="/img/css.css?random="><link data-rh="true" rel="icon" href="/img/favicon.ico"/><script data-ad-client="ca-pub-6067137220025946" async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script><script type="text/javascript" src="https://platform-api.sharethis.com/js/sharethis.js#property=5effb96910009800120b8d4d&product=inline-share-buttons" async="async"></script>
<script>var _hmt = _hmt || [];(function() {var hm = document.createElement("script");hm.src = "https://hm.baidu.com/hm.js?03c1a0f31299b4a2fbb83c34d6beaac9";var s = document.getElementsByTagName("script")[0]; s.parentNode.insertBefore(hm, s);})();</script></head><body><div id="my_header"><div class="container"><nav class="navbar navbar-expand-lg"><a class="navbar-brand" href="/"><img alt="diglog" src="/img/logo.v1.gif" class="rounded-sm"></a><button class="navbar-toggler" type="button" data-toggle="collapse" data-target="#navbarNavAltMarkup" aria-controls="navbarNavAltMarkup" aria-expanded="false" aria-label="Toggle navigation"><span class="navbar-toggler-icon"></span></button><div class="collapse navbar-collapse" id="navbarNavAltMarkup"><div class="navbar-nav"></div></div></nav></div></div><div class="container"><div id="my_content"><h1 class="page_narrow">The cancer vaccine roller coaster (2009)<br/>癌症疫苗过山车（2009）</h1><div class="row"><div class="col-lg-12 col-12"><div class="my_story_list_item shadow p-3 mb-5 bg-white rounded"><div class="story_page_pub_time page_narrow">2022-02-21 01:42:16</div><div class="page_narrow text-break page_content"><p>The cancer vaccine field is littered with promising products that failed to show clinical efficacy. Could it finally be on the verge of a first US approval?</p><p>癌症疫苗领域充斥着未能显示临床疗效的有前途的产品。它最终会在美国首次批准的边缘吗？</p><p>     If any field epitomizes the boom and bust cycles of biotech, it would be cancer vaccines. Over the years, numerous tumor immunotherapies have gone through rounds of early-stage successes, only to fail in phase 3 clinical trials. Experts point to many reasons for the failures, from “jumping the gun” before enough was known about the biology or the therapies to letting business considerations—going for low cost and short time lines—trump science; what Peter Bross, chief of clinical evaluations at the US Food and Drug Administration&#39;s (FDA&#39;s) Center for Biologicals Evaluation and Research calls companies simply not doing their homework. Put these problems together with poorly designed clinical trials of heterogeneous cancer patient populations with late-stage disease, add a lack of familiarity of the regulatory authorities in assessing tumor vaccine products, mix in manufacturing scale-up headaches and the resulting recipe is all but toxic to investors. As Bruce Booth of Atlas Ventures (Waltham, MA, USA) puts it, realizing the potential of cancer vaccines is “full of complexity.”</p><p>如果说有哪个领域是生物技术繁荣与萧条周期的缩影，那就是癌症疫苗。多年来，许多肿瘤免疫疗法经历了一轮又一轮的早期成功，但在第三阶段临床试验中失败。专家指出失败的原因有很多，从在对生物学或疗法了解足够多之前就“跳枪”，到让低成本、短时间的商业考虑凌驾于科学之上；美国食品和药物管理局（FDA）临床评估主管彼得·布罗斯（Peter Bross）39；美国食品和药物管理局（FDA）生物制品评估与研究中心（Center for Biological Evaluation and Research）呼吁企业不要做功课。将这些问题与针对患有晚期疾病的异质性癌症患者群体的设计不当的临床试验结合起来，再加上监管机构在评估肿瘤疫苗产品方面缺乏熟悉度，以及制造规模扩大带来的问题，由此产生的配方对投资者来说几乎是有毒的。正如Atlas Ventures（美国马萨诸塞州沃尔瑟姆）的布鲁斯·布斯（Bruce Booth）所说，实现癌症疫苗的潜力“充满复杂性”</p><p> But some researchers and analysts are keeping the faith, hoping that a more comprehensive understanding of tumor immunology will lead the way to more fruitful approaches ( Table 1). Several promising phase 3 programs are nearing completion, so 2009 may well be the year of the cancer vaccine. “There have been other technologies that failed in their first iteration.... As long as modifications are made and something new comes out of it, I think you&#39;ll generate interest,” says Reni Benjamin, senior biotech analyst at Rodman and Renshaw (New York).</p><p>但一些研究人员和分析人士仍坚持这一信念，希望对肿瘤免疫学有更全面的了解，从而找到更有效的方法（表1）。几个有希望的三期项目即将完成，因此2009年很可能是癌症疫苗的一年。Rodman and Renshaw（纽约）的高级生物技术分析师雷尼·本杰明（Reni Benjamin）说：“还有其他一些技术在第一次迭代中失败了……只要进行了修改，并从中产生了新的东西，我认为你会产生兴趣。”。</p><p> In the meantime, the question is whether there is enough money to support the approach in the coffers of biotechs or coming from the pharmaceutical industry, which has been burned repeatedly ( Table 2). And what lessons from the ever-growing list of failures—and some possible successes—will inform future practitioners in the field?</p><p>与此同时，问题是，生物技术公司的金库中是否有足够的资金来支持这一方法，还是来自制药行业，该行业已被反复烧毁（表2）。从不断增长的失败和一些可能的成功中吸取的教训将为该领域的未来从业者提供什么启示？</p><p>  Cancer vaccinology is predicated on the notion of awakening the immune system to the presence of cancer by presenting it with antigens associated with tumor cells. Once the immune system is roused, the concept is that it would be capable not only of mounting a sustained bodywide search for similarly suspicious cells, but also of retaining a memory of the abnormal antigens, permitting a renewed, rapid assault should the tumor recur.</p><p>癌症疫苗学的基础是，通过向免疫系统提供与肿瘤细胞相关的抗原，唤醒免疫系统对癌症的存在。一旦免疫系统被唤醒，其概念是，它不仅能够在全身范围内持续搜索类似的可疑细胞，还能够保留对异常抗原的记忆，从而在肿瘤复发时允许再次快速攻击。</p><p> The notion that the immune system could be enlisted to launch an attack on an existing tumor has been around at least since the late 1800s, when the New York City–based physician William Coley noticed that metastases at several sites regressed in a sarcoma patient after she developed a bacterial incision-wound infection. Coley&#39;s attempts to exploit this discovery were handicapped by the then-crude state of knowledge. But to this day, remnants of this approach can be seen in the use of general immune stimulants, like attenuated bacteria (e.g., mycobacterial components in Bacille Calmette Guerin, BCG) and interleukins, in treating bladder cancer and melanoma, respectively, as well as their inclusion in combination therapies in literally hundreds of clinical trials.</p><p>至少从19世纪末开始，免疫系统就可以对现有肿瘤发起攻击，当时纽约市的医生威廉·科利注意到，在一名肉瘤患者出现细菌切口感染后，几个部位的转移消退。科利和#39；美国试图利用这一发现的努力受到当时知识的原始状态的阻碍。但时至今日，这种方法的残余可以在使用普通免疫兴奋剂中看到，如减毒细菌（例如卡介苗中的分枝杆菌成分）和白细胞介素，分别用于治疗膀胱癌和黑色素瘤，以及在数百项临床试验中将其纳入联合疗法。</p><p> The discovery and identification of tumor-associated antigens, which now number in the hundreds (see  Table 3 for some examples), stimulated a second approach to cancer vaccines, an approach still highly visible among the therapies being tested today. Roughly half of ongoing clinical trials enlist a tumor-associated antigen or collection of antigens ( Fig. 1 and  Table 4). Many such trials have ended in failure, which we now know is because these antigens muster only weak immune responses because they are normal human proteins merely overexpressed on tumor cells (to which the patient would be tolerant) or they too closely resemble such proteins or they elicit only a weak response from the patient&#39;s compromised immune system. It is now known that multiple co-stimulatory signals are needed to generate a robust T-cell response against a tumor-associated antigen; if these signals are not supplied, T-cell anergy and peripheral tolerance follows. Such tepid immune responses are not nearly what would be needed to eradicate advanced cancers, which early on accounted for most patients treated in clinical trials. Contemporary trials using tumor-associated and more promising tumor-specific antigens now use various immune stimulatory molecules, such as granulocyte macrophage colony stimulating factor (GM-CSF), and generalized adjuvants, such as keyhole limpet hemocyanin (KLH), to boost the response.</p><p>肿瘤相关抗原的发现和鉴定，目前已有数百种（一些例子见表3），刺激了癌症疫苗的第二种方法，这种方法在今天正在测试的治疗中仍然非常明显。大约有一半正在进行的临床试验涉及肿瘤相关抗原或抗原集合（图1和表4）。许多这样的试验都以失败告终，我们现在知道这是因为这些抗原只能产生微弱的免疫反应，因为它们是正常的人类蛋白质，只是在肿瘤细胞上过度表达（患者可能会耐受），或者它们与这些蛋白质太过相似，或者它们只能引起患者的微弱反应#39；它的免疫系统受损。目前已知，需要多种共刺激信号来产生针对肿瘤相关抗原的强大T细胞反应；如果不提供这些信号，T细胞无能和外周耐受性随之出现。这种不温不火的免疫反应远不是根除晚期癌症所需要的，晚期癌症是临床试验中大多数患者早期接受治疗的原因。使用肿瘤相关和更具前景的肿瘤特异性抗原的当代试验现在使用各种免疫刺激分子（如粒细胞-巨噬细胞集落刺激因子（GM-CSF））和广义佐剂（如锁孔帽贝血蓝蛋白（KLH））来增强反应。</p><p> Many approaches have explicitly tried to engage cell-mediated immunity either using isolated antigen-presenting cells (APCs) or attempting to stimulate them  in situ ( Fig. 2). Techniques were developed for extracting dendritic cells, a major APC, loading them up with tumor antigens in various ways and reintroducing them into patients. Early attempts here failed, and in some cases, actually led to poorer outcomes than if the individual had been untreated, as immature dendritic cells, it was later learned, were as likely to suppress the immune system as to stimulate it. Methods for characterizing the right types of dendritic cell and other APCs are now being worked out, and it&#39;s become clearer how to activate these cells through cytokines, such as GM-CSF, to optimize antigen presentation (one such immunotherapeutic candidate in late-stage clinical trials, Dendreon&#39;s Provenge (Seattle; sipuleucel-T) for prostate cancer, may prove to be among the first therapeutic cancer vaccines to receive FDA approval;  Box 1).</p><p>许多方法已经明确尝试使用分离的抗原呈递细胞（APC）或试图原位刺激它们来参与细胞介导的免疫（图2）。人们开发了提取树突状细胞的技术，树突状细胞是一种主要的APC，以各种方式将肿瘤抗原装载到树突状细胞中，并将其重新导入患者体内。早期的尝试失败了，在某些情况下，实际上导致了比未经治疗的个体更糟糕的结果，因为后来发现，未成熟的树突状细胞既可能抑制免疫系统，也可能刺激免疫系统。描述树突状细胞和其他APC的正确类型的方法正在制定中，它&#39；如何通过细胞因子（如GM-CSF）激活这些细胞，以优化抗原呈递（晚期临床试验中的一种免疫治疗候选者，Dendreon&s Provenge（西雅图；sipuleucel-T））治疗前列腺癌，可能被证明是首批获得FDA批准的治疗性癌症疫苗之一；框注1）。</p><p> Just in the past five years, information has surfaced, pointing to a whole new problem with cancer immunotherapy—active immunosuppression in the tumor microenvironment. Tumors have been long suspected to evade immune detection by, for example, Darwinian evolution of cells whose defining surface antigens are suppressed or creating positive pressure gradients that make it harder for circulating immune cells to penetrate them ( Fig. 3). But now, it has emerged that in addition to evasion, tumors actually can induce local immunosuppression through the stimulation of regulatory T cells or the recruitment of myeloid-derived suppressor (MDS) cells. The former, primarily through their production of transforming growth factor (TGF)-β, inhibit CD8 + cytotoxic T cells (CTLs), T helper 1 (T H1) cells and natural killer (NK) cells, which are the main mediators of immune surveillance against tumors. MDS cells, a mixed population of relatively immature myeloid cells, also suppress cellular immune responses primarily by producing arginase 1 and nitric oxide synthase 2A.</p><p>就在过去五年里，信息浮出水面，指出了癌症免疫治疗的一个全新问题——肿瘤微环境中的主动免疫抑制。长期以来，人们一直怀疑肿瘤通过细胞的达尔文进化逃避免疫检测，例如，细胞的定义性表面抗原被抑制，或产生正压力梯度，使循环免疫细胞更难穿透它们（图3）。但现在，人们发现，除了逃避之外，肿瘤实际上还可以通过刺激调节性T细胞或招募髓源性抑制（MDS）细胞来诱导局部免疫抑制。前者主要通过产生转化生长因子（TGF）-β，抑制CD8+细胞毒性T细胞（CTL）、辅助性T细胞1（T H1）和自然杀伤细胞（NK），它们是肿瘤免疫监测的主要介质。MDS细胞是相对不成熟的髓样细胞的混合群体，也主要通过产生精氨酸酶1和一氧化氮合酶2A来抑制细胞免疫反应。</p><p> (Reprinted from Whiteside, T.L. Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention.  Semin. Cancer Biol.  16, 3–15, 2006, with permission from Elsevier.)</p><p>（转载自Whiteside，T.L.癌症中的免疫抑制：对免疫细胞的影响、机制和未来的治疗干预。Semin.cancer Biol.16，3–15，2006，获得爱思唯尔的许可。）</p><p> One means of potentiating the power of cancer vaccines and unleashing the immune system, according to leading academics, would be to counteract tumor-mediated immune suppression. This could be accomplished by targeting the regulators of the regulators, so to speak. For example, several molecules have been identified (e.g., CTL antigen 4, CTLA-4) that engage with regulatory T cells. Animal studies have shown that blocking such interactions, either with monoclonal antibodies (mAbs) or gene knockouts abrogates immune suppression. Indeed, several dozen clinical trials, according to the US National Institutes of Health ( http://www.clinicaltrials.gov), are currently underway using mAbs against CTLA-4 in combination with chemotherapy or vaccines.</p><p>根据顶尖学者的说法，增强癌症疫苗威力和释放免疫系统的一种方法是对抗肿瘤介导的免疫抑制。可以说，这可以通过针对监管者中的监管者来实现。例如，已经确定了几个与调节性T细胞结合的分子（例如CTL抗原4、CTLA-4）。动物研究表明，用单克隆抗体（MAB）或基因敲除物阻断这种相互作用可以消除免疫抑制。事实上，根据美国国立卫生研究院（National Institutes of Health，简称NIH）的数据，已有数十项临床试验http://www.clinicaltrials.gov)目前正在联合化疗或疫苗使用抗CTLA-4的单克隆抗体。</p><p>  Cancer immunotherapy means different things to different people. In the case of cancers that are known to express viral antigens (e.g., cervical cancer and some melanomas that express human papilloma virus), immunotherapy takes the form of a classic immunoprotective, prophylatic vaccine like smallpox or polio where a viral antigen is presented to the immune system. In those cases where cancers overexpress a particular endogenous surface antigen (e.g., Her-2 in some breast cancers or CD-20 in some lymphoma cells), mAbs directed against those surface markers (Genentech&#39;s Herceptin (trastuzumab) and Genentech&#39;s and Biogen-Idec&#39;s Rituxan (rituximab), respectively) provide passive immunity, which can keep a tumor in check for a while. There are many such mAbs for various cancers under development. As currently applied, these mAbs are not preventive but rather therapeutic, though Herceptin has been approved for ever earlier stages in breast cancer, where it might, at least in theory, protect against recurrences by preventing metastases from taking hold.</p><p>癌症免疫治疗对不同的人意味着不同的事情。对于已知表达病毒抗原的癌症（例如，宫颈癌和一些表达人乳头状瘤病毒的黑色素瘤），免疫治疗采取经典的免疫保护性预防性疫苗的形式，如天花或脊髓灰质炎，病毒抗原被呈递给免疫系统。在癌症过度表达特定内源性表面抗原的情况下（例如，某些乳腺癌中的Her-2或某些淋巴瘤细胞中的CD-20），针对这些表面标记物的单克隆抗体（Genentech和#39；s Herceptin（曲妥珠单抗）和Genentech和#39；s和Biogen Idec&#39；美罗华（分别是利妥昔单抗）提供被动免疫，可以在一段时间内控制肿瘤。目前有许多针对各种癌症的单克隆抗体正在研发中。就目前的应用而言，这些单克隆抗体不是预防性的，而是治疗性的，尽管赫赛汀已被批准用于乳腺癌的早期阶段，至少在理论上，它可能通过防止转移来防止复发。</p><p> Active immunotherapies, on the other hand, are designed to incite the individual&#39;s own immune system to mount a response to an antigen or group of antigens exclusive to or predominantly associated with the patient&#39;s tumor. They can take the form of peptide/protein vaccines or cellular vaccines.</p><p>另一方面，主动免疫疗法旨在激发个体#39；自身免疫系统对患者独有或主要与患者相关的抗原或抗原组产生反应&#39；这是肿瘤。它们可以采取肽/蛋白质疫苗或细胞疫苗的形式。</p><p> The former type of vaccine generally falls into two categories. The first is based on shared peptide or protein antigens that occur commonly in a particular cancer or group of cancers (epidermal growth factor receptor (EGFR) vIII, for example, which is found in 30–40% of glioblastomas, or MAGE-3, which is expressed on many lung tumors). The proteins can be injected directly or expressed on attenuated virus particles, or nonproliferative bacterial or yeast cells ( Box 2). An alternative approach is to isolate antigens from an individual patient and present these back to the person in a form designed to elicit immune surveillance, such as vaccines designed to stimulate responses against antibody idiotypes found on lymphomas or the use of heat shock proteins to present unique tumor peptides ( Box 3).</p><p>前一种疫苗一般分为两类。第一种是基于特定癌症或癌症组中常见的共享肽或蛋白质抗原（例如，表皮生长因子受体（EGFR）vIII，在30–40%的胶质母细胞瘤中发现，或MAGE-3，在许多肺癌中表达）。这些蛋白质可以直接注射或在减毒病毒颗粒、非增殖细菌或酵母细胞上表达（框2）。另一种方法是从单个患者中分离抗原，并以设计用于引发免疫监测的形式将其呈现给患者，例如设计用于刺激针对淋巴瘤上发现的抗体独特型的反应的疫苗，或使用热休克蛋白呈现独特的肿瘤肽（框3）。</p><p> Cellular cancer vaccines can also be divided into two broad groups: allogeneic or autologous. The former, so-called &#39;off-the-shelf&#39; vaccines, are usually collections of tumor cell lines, administered as aggregates to present several potential tumor antigens to the patient&#39;s immune system. Autologous whole cells, on the other hand, are isolated from, and returned to, individuals after some  ex vivo manipulation to activate or induce maturation of APCs. An example of this type of vaccine would be a product based on isolation of APCs from a patient that is engineered to express some soluble factor (or factors) that generates an immune response to a common antigen (e.g., prostate-specific antigen in the case of prostate cancer, or p53/telomerase more generally ( Box 1)).</p><p>细胞癌疫苗也可分为两大类：同种异体或自体。前者，即所谓的&#39；现成的#39；疫苗通常是肿瘤细胞系的集合，作为聚合体给患者提供几种潜在的肿瘤抗原#39；人类的免疫系统。另一方面，自体全细胞在体外操作以激活或诱导APC成熟后，从个体中分离并返回给个体。这类疫苗的一个例子是基于从患者中分离APC的产品，该产品被设计为表达一些可溶性因子（或多个因子），这些因子产生对共同抗原的免疫反应（例如，前列腺癌的前列腺特异性抗原，或者更广泛地说是p53/端粒酶（框1））。</p><p> Compared with cellular vaccines, peptide vaccines have the advantage of being similar to existing vaccine approaches used for decades in immunization programs against infectious agents. Such vaccines are less tricky to manufacture on a large scale than cellular vaccines. In 2002, for example, the FDA placed a hold on CancerVax&#39;s (Carlsbad, CA, USA) phase 3 trial of cellular vaccine Canvaxin because of manufacturing concerns. What&#39;s more, the longer clinical history and widespread use of peptide/protein vaccines means that regulators are more familiar with their oversight and less likely to raise issues unanticipated by product sponsors.</p><p>与细胞疫苗相比，肽疫苗的优点是与几十年来在针对传染源的免疫计划中使用的现有疫苗方法相似。与细胞疫苗相比，这种疫苗的大规模生产难度更小。例如，2002年，FDA暂停了CancerVax&#39；s（美国加利福尼亚州卡尔斯巴德）细胞疫苗Canvaxin的3期试验，因为生产方面的问题。什么&#39；此外，更长的临床病史和肽/蛋白质疫苗的广泛使用意味着监管机构更熟悉他们的监管，也不太可能提出产品赞助商意想不到的问题。</p><p>  Cancer vaccines represent a relatively small portion of the oncology drugs in commercial development. The Tufts Center for the Study of Drug Development (Boston) reports that only one-fifth of oncology biologic therapeutics in company pipelines are vaccines ( Fig. 4). Although modern cancer vaccine development dates back to the 1980s, none has been approved in the United States (though there are five products on the market elsewhere;  Table 5). Thus, the rate of approval of cancer vaccines lags far behind other biologics—as of 2006, seven of twelve vaccines in phase 3 clinical trials had entered clinical study a decade earlier.</p><p>癌症疫苗在商业开发的肿瘤药物中所占比例相对较小。塔夫茨药物开发研究中心（波士顿）报告称，公司管道中仅有五分之一的肿瘤生物疗法是疫苗（图4）。尽管现代癌症疫苗的开发可以追溯到20世纪80年代，但美国尚未批准任何一种疫苗（尽管其他地方市场上有五种产品；表5）。因此，癌症疫苗的批准率远远落后于其他生物制品。截至2006年，三期临床试验的12种疫苗中有7种在十年前进入临床研究。</p><p> To date, an estimated 7,000 people have participated in late-stage clinical trials of active cancer immunotherapies. These have largely been an exercise in frustration, as candidates—including a few that looked quite good in early trials—have fallen by the wayside in pivotal phase 3 trials. Some recent losers that have gone quietly into the night:</p><p>迄今为止，估计有7000人参与了癌症主动免疫疗法的晚期临床试验。这在很大程度上是一种挫败感，因为候选人，包括一些在早期试验中看起来相当不错的候选人，在关键的第三阶段试验中被搁置了。一些最近的失败者已经悄然入夜：</p><p> PANVAC (Therion Biologics, Cambridge, MA, USA), an off-the-shelf vaccine consisting of attenuated poxvirus carrying genes encoding two tumor-associated antigens (carcinoembryonic antigen and mucin 1, MUC-1) and three immunostimulatory molecules (intracellular adhesion molecule 1, B7.1 and lymphocyte function–associated molecule 3) for use in advanced pancreatic cancer, failed to meet clinical endpoints after promising early trials, leading the company to close its doors and file for bankruptcy protection in December 2006.</p><p>PANVAC（美国马萨诸塞州剑桥市塞里昂生物制品公司），一种现成的疫苗，由携带编码两种肿瘤相关抗原（癌胚抗原和粘蛋白1，MUC-1）和三种免疫刺激分子（细胞内粘附分子1，B7.1和淋巴细胞功能相关分子3）的基因的减毒痘病毒组成，用于晚期胰腺癌，在承诺进行早期试验后未能达到临床终点，导致该公司于2006年12月关闭大门并申请破产保护。</p><p>  Theratope (Biomira, Edmunton, AB, Canada; now Oncothyreon, Seattle), an off-the-shelf vaccine, consisting of a synthetic mimic (STn-crotyl) of the tumor-associated,  O-linked epitope of MUC-1 (STn-serine), tethered to an immunostimulatory protein (KLH) and delivered along with an adjuvant from Seattle-based Corixa (Detox-B, an oil droplet emulsion containing monophosphoryl lipid A and cell wall skeleton from  Mycobacterium phlei) for use in metastatic breast cancer, showed no improvement in either time to progression or overall survival. The company hasn&#39;t completely abandoned the target; in partnership with Merck KGaA (Darmstadt, Germany), it has developed a “more sophisticated” approach for eliciting a T-cell response, according to Marita Hobman, director of intellectual property management and business development at Oncothyreon.</p><p>Theratope（加拿大AB州埃德蒙顿的Biomira；现为西雅图的Onocythreon）是一种现成的疫苗，由MUC-1（STn丝氨酸）的肿瘤相关O-连接表位的合成模拟物（STn crotyl）组成，与免疫刺激蛋白（KLH）相连，并与西雅图Corixa（解毒-B，一种含有单磷酸脂A和草分枝杆菌细胞壁骨架的油滴乳剂）提供的佐剂一起用于转移性乳腺癌，在进展时间或总体生存率方面均无改善。该公司没有&#39；不要完全放弃目标；Onocythreon的知识产权管理和业务发展总监玛丽塔·霍布曼（Marita Hobman）表示，该公司与默克KGaA（德国达姆施塔特）合作，开发了一种“更复杂”的方法来激发T细胞反应。</p><p>  Canvaxin (CancerVax, now MicroMet, Munich), an off-the-shelf mix of three irradiated melanoma cell lines bearing over a dozen defined tumor-associated antigens, plus an adjuvant (BCG) for use in stage III melanoma, yielded worse outcomes in treated patients than in controls, unlike earlier trials in which patients had been more carefully selected for human leukocyte antigen (HLA) alleles correlating with better outcomes. After Canvaxin failed, CancerVax merged with Micromet, which is developing passive immunotherapies using mAbs against various tumor antigens.</p><p>Canvaxin（CancerVax，现为慕尼黑MicroMet）是一种由三种辐照黑色素瘤细胞系组成的现成混合物，含有十几种特定的肿瘤相关抗原，加上一种用于III期黑色素瘤的佐剂（BCG），治疗后患者的预后比对照组差，与早期的试验不同，在早期的试验中，患者被更仔细地选择与更好的结果相关的人类白细胞抗原（HLA）等位基因。Canvaxin失败后，CancerVax与Micromet合并，Micromet正在开发针对各种肿瘤抗原的单克隆抗体的被动免疫疗法。</p><p>  GVAX (Cell Genesys, S. San Francisco, CA, USA), an off-the-shelf, whole-cell vaccine, consisting of infusions of cells from existing prostate cancer lines engineered to express GM-CSF for use in hormone-refractory prostate cancer, yielded excess deaths in treated patients versus controls, leading to abandonment of the trial.</p><p>GVAX（Cell GeNeSys，S.旧金山，CA，美国），一种现成的全细胞疫苗，由现有的前列腺癌细胞的细胞输注组成，用于在激素难治性前列腺癌中表达GM-CSF，在治疗的患者与对照组之间产生了额外的死亡，导致放弃试验。</p><p> Although there is a clear preponderance of off-the-shelf vaccines in this group of failures, the fate of individualized vaccines has not necessarily been much better. Two companies with vaccines targeting antibody idiotypes associated with tumors—Favrille (San Diego) and Genitope (Fremont, CA, USA)—both shut down their trials when their products failed to reach statistical significance, essentially ending their programs in late 2008.</p><p>尽管在这组失败案例中，现成疫苗占明显优势，但个体化疫苗的命运并不一定好得多。两家公司生产的疫苗针对的是与肿瘤相关的抗体独特型——Favrille（圣地亚哥）和Genitope（美国加利福尼亚州弗里蒙特市）——由于产品未能达到统计显著性，两家公司都停止了试验，基本上在2008年底结束了项目。</p><p>  A cancer vaccine has to jump through several hoops, says Johns Hopkins University oncologist Hyam Levitsky, co-inventor of GVAX and member of the board of the cancer vaccine company Antigenics (New York). “In an existing tumor, the body has already been exposed to those antigens, so there may already have been an initial immune response. But very often, the immune system is defeated and rendered tolerant to the antigens that the vaccine is targeting. A successful vaccine has to overcome this tolerance, and that&#39;s not trivial.” Moreover, Levitsky says, the vaccine frequently has to work in what can be a hostile environment. “The tumor has essentially taken over and altered the landscape, stealing various attributes of the normal immune system to turn down immune response.”</p><p>约翰·霍普金斯大学肿瘤学家海姆·莱维茨基（Hyam Levitsky）说，一种癌症疫苗必须跨越几个障碍。海姆·莱维茨基是GVAX的共同发明者，也是癌症疫苗公司Antigenics（纽约）的董事会成员。“在现有的肿瘤中，身体已经暴露于这些抗原，因此可能已经有了最初的免疫反应。但通常情况下，免疫系统会被破坏，并对疫苗所针对的抗原产生耐受性。成功的疫苗必须克服这种耐受性，这并不是小事。”此外，莱维茨基说，疫苗经常必须在可能是敌对的环境中工作。“肿瘤实质上占据并改变了环境，窃取了正常免疫系统的各种属性，从而降低了免疫反应。”</p><p> The antigens to use in a vaccine to circumvent the challenge of breaking immune tolerance without generating autoimmunity should be tumor specific. But such antigens are rarely found, says Jeffrey Weber, head of the Comprehensive Melanoma Research Center at the H. Lee Moffitt Cancer Center (Tampa, FL, USA). “These are few and far between. You can discover any number of mutated, tumor-specific antigens, but you seldom find any that turn up on more than 5% of tumors of any given type.” And even when you find one, he says, that doesn&#39;t mean it will be highly immunogenic.</p><p>疫苗中用来规避破坏免疫耐受而不产生自身免疫的抗原应该是肿瘤特异性的。但H.Lee Moffitt癌症中心（美国佛罗里达州坦帕市）黑色素瘤综合研究中心主任杰弗里·韦伯说，这种抗原很少被发现。“这是非常罕见的。你可以发现任何数量的突变的肿瘤特异性抗原，但在任何特定类型的肿瘤中很少发现超过5%的突变抗原。”他说，即使你找到了一个，那也不会&#39；这并不意味着它具有高度的免疫原性。</p><p> In practice, cancer antigens targeted by active immunotherapies have more often been tumor associated: overexpressed on tumors, but nonetheless present at lower frequencies in normal tissues. In trials of vaccines based on these antigens, the necessity of breaking tolerance—for example, by pairing the selected antigen with a powerful adjuvant—has clashed with the need to avoid an excessive immune assault on healthy tissues where the antigen also resides. “You can vaccinate the hell out of somebody against melanoma self-antigens that are overexpressed on cancer, and you won&#39;t induce severe side effects—or any immune response to speak of,” says Weber. “But if you administer the same vaccine along with one dose of anti-CTLA-4 antibodies, you can induce life-threatening autoimmune colitis or skin rash or hepatitis.”</p><p>在实践中，主动免疫疗法靶向的癌症抗原更常与肿瘤相关：在肿瘤上过度表达，但在正常组织中出现的频率较低。在基于这些抗原的疫苗试验中，打破耐受性的必要性（例如，通过将选定的抗原与强大的佐剂配对）与避免对抗原同样存在的健康组织进行过度免疫攻击的必要性发生了冲突。韦伯说：“你可以给某人注射疫苗，对抗在癌症中过度表达的黑色素瘤自身抗原，这样你就不会产生严重的副作用或任何免疫反应。”。“但如果你同时接种同一种疫苗和一剂抗CTLA-4抗体，你可能会诱发危及生命的自身免疫性结肠炎、皮疹或肝炎。”</p><p> Another problem plaguing trials of cancer immunotherapies has been the intractability of the cancers targeted. In theory, any cancer should be amenable to immunotherapy, but in practice, only a few cancers have received most of the attention, at least historically. Melanoma, which early on was found to have tumor-specific antigens, has been targeted frequently using the protein or peptide approach—mostly without success, as no really tumor-specific melanoma antigens have yet been exploited, only tumor-associated antigens. But those cell-based approaches, in which autologous proteins or extracts are used for priming, require access to a sufficient tumor mass. This more or less excludes melanoma or even breast cancer, where the tissue tends to be fibrotic and where tumors tend to be diagnosed increasingly early, while they are still relatively small.</p><p>另一个困扰癌症免疫治疗试验的问题是靶向癌症的难治性。从理论上讲，任何癌症都应该接受免疫治疗，但在实践中，只有少数癌症得到了大多数关注，至少在历史上是如此。黑色素瘤在早期被发现具有肿瘤特异性抗原，但由于没有真正的肿瘤特异性黑色素瘤抗原被开发，只有肿瘤相关抗原，因此经常使用蛋白质或肽方法来靶向黑色素瘤，但大多没有成功。但那些基于细胞的方法，即使用自体蛋白质或提取物进行启动，需要获得足够的肿瘤肿块。这或多或少地排除了黑色素瘤，甚至乳腺癌，那里的组织往往是纤维化的，肿瘤往往被诊断得越来越早，而它们仍然相对较小。</p><p> Recognizing that the immune response takes time to develop, some vaccine developers have turned to slow-growing prostate cancer or kidney tumors, where the time to progression is longer. And then, of course, greater prevalence of certain tumor types, such as lung, create a large patient pool with which to populate clinical trials, whereas the dearth of decent treatments for these indications speaks most loudly to the need for ramped-up clinical experimentation.</p><p>由于认识到免疫反应需要时间才能形成，一些疫苗研发人员已经转向生长缓慢的前列腺癌或肾肿瘤，这些肿瘤的进展时间更长。当然，某些肿瘤类型（如肺）的更高患病率创造了一个庞大的患者库，可以用来填充临床试验，而这些适应症缺乏适当的治疗方法最有力地说明了加强临床试验的必要性。</p><p> Certainly, the tendency to use individuals who are in advanced cancer stages has made proof of clinical efficacy more difficult to achieve. Of course, individuals with late-stage disease, who have often been treated with other therapeutic agents that have failed, tend to be more available. And sponsoring companies prefer this population because they expect that positive treatment effects will be observed more quickly in advanced-stage patients than in early-stage or fully resected ones. But decades&#39; worth of clinical trials of cancer vaccines conducted across multiple tumor types not surprisingly suggest that immunotherapies are more likely to work best in patients with earlier-stage, less-aggressive tumors  1 or in individuals whose tumor burden has been reduced to the microscopic level by surgery or chemotherapy.</p><p>当然，使用处于晚期癌症阶段的个体的趋势使得临床疗效的证明更加难以实现。当然，患有晚期疾病的患者往往更容易获得治疗，他们经常使用其他治疗药物治疗，但治疗失败。赞助公司更喜欢这一人群，因为他们希望晚期患者的积极治疗效果比早期或完全切除的患者更快观察到。但是几十年&#39；在多种肿瘤类型中进行的癌症疫苗临床试验的价值不足为奇地表明，免疫疗法更有可能在早期、侵袭性较低的肿瘤患者1或通过手术或化疗将肿瘤负担降低到显微镜水平的个体中发挥最佳效果。</p><p> “It&#39;s at this level of microscopic disease where I think cancer vaccines are most likely to succeed,” Levitsky says. “Well over 50% of the common cancers can be treated into a state of minimal residual disease. What we lose patients to is typically not the inability to get the disease into that minimal state, but rather the inability to completely eradicate the residual component.” All too often, a seemingly excised tumor returns. “Fro</p><p>莱维茨基说：“我认为癌症疫苗最有可能在这种微观疾病水平上取得成功。”。“超过50%的常见癌症可以被治疗成一种残留极少的疾病状态。我们让患者失去的通常不是无法使疾病进入这种最小状态，而是无法完全消除残留成分。”通常情况下，一个看似切除的肿瘤会复发。“向前</p><p>......</p><p>......</p></div><div id="story_share_this"><div class="sharethis-inline-share-buttons"></div></div><div class="story_tags page_narrow"><button type="button" class="btn btn-light my_tag"><a href="/tag/疫苗/">#疫苗</a></button><button type="button" class="btn btn-light my_tag"><a href="/tag/vaccine/">#vaccine</a></button><button type="button" class="btn btn-light my_tag"><a href="/tag/肿瘤/">#肿瘤</a></button></div></div><div class="my_movie_list_item shadow p-3 mb-5 bg-white rounded"><button type="button" class="btn btn-link my_tag"><a href="/tag/web2.0/">#web2.0</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/google/">#google</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/设计/">#设计</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/创意/">#创意</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/摄影/">#摄影</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/图片/">#图片</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/游戏/">#游戏</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/软件/">#软件</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/广告/">#广告</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/视频/">#视频</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/手机/">#手机</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/iphone/">#iphone</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/网站/">#网站</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/免费/">#免费</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/windows/">#windows</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/下载/">#下载</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/微软/">#微软</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/苹果/">#苹果</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/firefox/">#firefox</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/blog/">#blog</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/音乐/">#音乐</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/博客/">#博客</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/apple/">#apple</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/wordpress/">#wordpress</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/恶搞/">#恶搞</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/qq/">#qq</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/谷歌/">#谷歌</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/艺术/">#艺术</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/web/">#web</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/工具/">#工具</a></button></div></div></div><div id="my_footer"><div class=""><a href="/tags/">tags</a> <a href="/users/">users</a></div>&copy;2012-2021 diglog.com </div></div></body></html>